Download Ranibizumab and pegaptanib for the treatment of age-related macular degeneration PDF

TitleRanibizumab and pegaptanib for the treatment of age-related macular degeneration
LanguageEnglish
File Size1.2 MB
Total Pages238
Table of Contents
                            Health Technology Assessment 2008; Vol. 12: No. 16
NIHR Health Technology Assessment Programme
Abstract
Contents
Glossary and list of abbreviations
Executive summary
Chapter 1
Background
	Description of health problem
	Current service provision
	Description of technology under
assessment
Chapter 2
Definition of the decision problem
	Decision problem
	Overall aims and objectives of
assessment
Chapter 3
Assessment of clinical effectiveness
	Methods for reviewing
effectiveness
	Results
	Discussion of clinical effectiveness
	Summary of clinical effectiveness
Chapter 4
Assessment of cost-effectiveness
	Introduction
	Systematic review of existing
cost-effectiveness evidence
	Independent economic
assessment
Chapter 5
Assessment of factors relevant to the NHS and
other parties
Chapter 6
Discussion
	Statement of principal findings
	Strengths and limitations of the
assessment
	Uncertainties
	Other relevant factors
Chapter 7
Conclusions
	Implications for service provision
	Suggested research priorities
Acknowledgements
References
Appendix 1
Protocol methods
Appendix 2
Literature search strategies
Appendix 3
Quality assessment
Appendix 4
Data extraction tables
Appendix 5
List of selected excluded studies
Appendix 6
List of eligible abstracts
Appendix 7
List of ongoing studies
Appendix 8
Critique of industry submissions
Appendix 9
Ocular adverse events in study eye: CIC information
from ranibizumab studies
Appendix 10
Non-ocular adverse events: CIC information from
ranibizumab studies
Appendix 11
Summary of measures reported in studies included
in the review of quality of life in AMD
Appendix 12
Critical appraisal checklist of economic evaluation in
Pfizer submission
Appendix 13
Critical appraisal checklist of economic evaluation in
Novartis submission
Appendix 14
Variables included in probabilistic sensitivity analysis
Appendix 15
Additional analysis commissioned by the NHS R&D
HTA Programme on behalf of the National Institute
for Health and Clinical Excellence
Health Technology Assessment reports
published to date
Health Technology Assessment
Programme
                        
Document Text Contents
Page 1

Ranibizumab and pegaptanib for the
treatment of age-related macular
degeneration: a systematic review
and economic evaluation

JL Colquitt, J Jones, SC Tan, A Takeda, AJ Clegg
and A Price

Health Technology Assessment 2008; Vol. 12: No. 16

HTAHealth Technology AssessmentNHS R&D HTA Programme
www.hta.ac.uk

The National Coordinating Centre for Health Technology Assessment,
Alpha House, Enterprise Road
Southampton Science Park
Chilworth
Southampton SO16 7NS, UK.
Fax: +44 (0) 23 8059 5639 Email: [email protected]
http://www.hta.ac.uk ISSN 1366-5278

Feedback
The HTA Programme and the authors would like to know

your views about this report.

The Correspondence Page on the HTA website
(http://www.hta.ac.uk) is a convenient way to publish

your comments. If you prefer, you can send your comments
to the address below, telling us whether you would like

us to transfer them to the website.

We look forward to hearing from you.

May 2008

H
ealth Technology Assessm

ent 2008;V
ol. 12: N

o. 16
R

anibizum
ab and pegaptanib for the treatm

ent of age-related m
acular degeneration

Copyright notice

© Queen's Printer and Controller of HMSO 2008

HTA reports may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising

Violations should be reported to [email protected]

Applications for commercial reproduction should be addressed to HMSO, The Copyright Unit, St Clements House, 2–16 Colegate, Norwich NR3 1BQ

Page 2

How to obtain copies of this and other HTA Programme reports.
An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of
charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is
also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and
private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is
£2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

– fax (with credit card or official purchase order)
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your
order and then post or fax it.

Contact details are as follows:
HTA Despatch Email: [email protected]
c/o Direct Mail Works Ltd Tel: 02392 492 000
4 Oakwood Business Centre Fax: 02392 478 555
Downley, HAVANT PO9 2NP, UK Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of
£100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300
per volume. Please see our website for details. Subscriptions can only be purchased for the current or
forthcoming volume.

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd
and drawn on a bank with a UK address.

Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard,
Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.
We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see
contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various
committees.

HTA

Page 119

102. Heier J, Boyer J, Ciulla D, Ferrone T, Jumper P,
Gentile J, et al. Ranibizumab combined with
verteportin photodynamic therapy in neovascular
age-related macular degeneration: year 1 results of
the FOCUS study. Arch Ophthalmol 2006;
124:1532–42.

103. Spaide R. New treatments for AMD. Ophthalmology
2006;113:160–1.

104. FDA Center for Drug Evaluation and Research.
Medical Officer’s review of NDA 21-756 – Macugen
final label. December 2004. URL:
http://www.fda.gov/cder/foi/nda/2004/21-
756_macugen_medr.pdf

105. Pfizer. Macugen (pegaptanib sodium). Submission to
the National Institute for Health and Clinical
Excellence, 31 July 2006.

106. Zlateva G, Patel M, Shah G, VEGF Inhibition
Study in Ocular Neovascularization (VISION)
Clinical Trial Group. Quality of life in patients
with age-related macular degeneration: results
from the VISION study. Invest Ophthalmol Vis Sci
2006;47:E-Abstract 2152.

107. EyeTech Pharmaceuticals. Dermatologic and
Ophthalmic Drugs Advisory Committee meeting.
Pegaptanib sodium injection (Macugen). PowerPoint
presentation, 2004. URL: http://www.fda.gov/
ohrms/dockets/ac/04/slides/2004-4053S1_01_
EyeTech-Main.ppt. Accessed 23 October 2006.

108. Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM,
Graham CN, Brogan AJ, et al. Cost-effectiveness
model for age-related macular degeneration:
Comparing Macugen to Visudyne. Value Health
2005;8:A176–7.

109. Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM,
Graham CN, Brogan AJ, et al. Cost-effectiveness
model for age-related macular degeneration:
comparing early and late macugen treatment.
Value Health 2005;8:A177.

110. Earnshaw SR, Javitt JC, Graham CN, Brogan AJ,
Zlateva GP, Pleil AM, et al. Modeling treatments
for subfoveal choroidal neovascularization
secondary to age related macular degeneration:
cost-effectiveness methods. Value Health 2005;
8:A179.

111. Bressler NM, Arnold J, Benchaboune M,
Blumenkranz MS, Fish GE, Gragoudas ES, et al.
Verteporfin therapy of subfoveal choroidal
neovascularization in patients with age-related
macular degeneration: additional information
regarding baseline lesion composition’s impact on
vision outcomes – TAP report no. 3. Arch
Ophthalmol 2002;120:1443–54.

112. Arnold J, Barbezetto I, Birngruber R, Bressler NM,
Bressler SB, Donati G, et al. Verteporfin therapy of
subfoveal choroidal neovascularization in age-
related macular degeneration: two-year results of a
randomized clinical trial including lesions with
occult with no classic choroidal neovascularization

– Verteporfin in photodynamic therapy report 2.
Am J Ophthalmol 2001;131:541–60.

113. Brown GC, Sharma S, Brown MM, Kistler J. Utility
values and age-related macular degeneration. Arch
Ophthalmol 2000;118:47–51.

114. Brown GC, Brown MM, Campanella J,
Beauchamp GR. The cost–utility of photodynamic
therapy in eyes with neovascular macular
degeneration – a value-based reappraisal with
5-year data. Am J Ophthalmol 2005;140:679–87.

115. Hopley C, Salkeld G, Mitchell P. Cost utility of
photodynamic therapy for predominantly classic
neovascular age related macular degeneration.
Br J Ophthalmol 2004;88:982–7.

116. Sharma S, Brown GC, Brown MM, Hollands H,
Shah GK. The cost-effectiveness of photodynamic
therapy for fellow eyes with subfoveal choroidal
neovascularization secondary to age-related
macular degeneration. Ophthalmology 2001;
108:2051–9.

117. Sharma S, Bakal J, Sharma SM, Covert D,
Shah GK. Drug pricing for a novel treatment for
wet macular degeneration: using incremental cost-
effectiveness ratios to ensure societal value. Can J
Ophthalmol 2005;40:369–77.

118. Greiner R-A. Cost of care for patients with age-
related macular degeneration in Switzerland and
cost-effectiveness of treatment with verteporfin
therapy. Semin Ophthalmol 2001;16:218–22.

119. Barry SJ, Douglas PR, Becker DL, Hughes MS,
Weinstein MC. Economic evaluation of
photodynamic therapy (Visudyne®) compared to
usual care in the treatment of age related macular
degeneration (ARMD) in USA. Value Health 2006;
9:A141–2.

120. Sharma S, Oliver-Fernandez A, Bakal P, Brown GC,
Brown MM. Cost–utility of vitamins for the
treatment of macular degeneration. Value Health
2002;5:553–4.

121. Scilley K, DeCarlo DK, Wells J, Owsley C. Vision-
specific health-related quality of life in age-related
maculopathy patients presenting for low vision
services. Ophthalmic Epidemiol 2004;11:131–46.

122. Miskala PH, Hawkins BS, Mangione CM, Bass EB,
Bressler NM, Dong LM, et al. Responsiveness of
the National Eye Institute Visual Function
Questionnaire to changes in visual acuity:
findings in patients with subfoveal choroidal
neovascularization – SST Report No. 1 [published
erratum appears in Arch Ophthalmol. 2003;
121:1513]. Arch Ophthalmol 2003;121:531–9.

123. DeCarlo DK, Scilley K, Wells J, Owsley C. Driving
habits and health-related quality of life in patients
with age-related maculopathy. Optometry Vis Sci
2003;80:207–13.

124. Hawkins BS. Health- and vision-related quality of
life among patients with ocular histoplasmosis or

Health Technology Assessment 2008; Vol. 12: No. 16

105

© Queen’s Printer and Controller of HMSO 2008. All rights reserved.

Page 120

idiopathic choroidal neovascularization at
enrollment in a randomized trial of submacular
surgery: Submacular Surgery Trials Report No. 5.
Arch Ophthalmol 2005;123:78–88.

125. Berdeaux GH, Nordmann JP, Colin E, Arnould B.
Vision-related quality of life in patients suffering
from age-related macular degeneration. Am J
Ophthalmol 2005;139:271–9.

126. Mitchell J, Wolffsohn JS, Woodcock A,
Anderson SJ, McMillan CV, Ffytche T, et al.
Psychometric evaluation of the MacDQoL
individualised measure of the impact of macular
degeneration on quality of life. Health Qual Life
Outcomes 2005;3:25–39.

127. Mangione CM, Gutierrez PR, Lowe G, Orav EJ,
Seddon JM. Influence of age-related maculopathy
on visual functioning and health-related quality of
life. Am J Ophthalmol 1999;128:45–53.

128. Armbrecht AM, Aspinall PA, Dhillon B.
A prospective study of visual function and quality
of life following PDT in patients with wet age
related macular degeneration. Br J Ophthalmol
2004;88:1270–3.

129. Brown GC, Brown MM, Sharma S. Difference
between ophthalmologists’ and patients’
perceptions of quality of life associated with age-
related macular degeneration. Can J Ophthalmol
2000;35:127–33.

130. Wakker P, Stiggelbout A. Explaining distortions in
utility elicitation through the rank-dependent
model for risky choices. Med Decis Making 1995;
15:180–6.

131. Stein JD, Brown MM, Brown GC, Hollands H,
Sharma S. Quality of life with macular
degeneration: perceptions of patients, clinicians,
and community members. Br J Ophthalmol 2003;
87:8–12.

132. Drummond MF, O’Brien BJ, Torrance GW,
Stoddart GL. Methods for the economic evaluation of
health care programmes. Oxford: Oxford University
Press; 1997.

133. National Institute for Clinical Excellence. Guide to
the Methods of Technology Appraisal. London: NICE;
2004.

134. Philips Z, Ginnelly L, Sculpher M, Claxton K,
Golder S, Riemsma R, et al. Review of guidelines
for good practice in decision-analytic modelling in
health technology assessment. Health Technol Assess
2004;8(36).

135. Curtis L, Netten A. Unit costs of health and social
care. Canterbury: Personal Social Services Research
Unit, University of Kent; 2005.

136. Zhou SWD. The economic burden of progression in
vision loss in Medicare beneficiaries, 1999 to 2003.
Data on file. Surrey, UK: Pfizer; 2004.

137. Office for National Statistics. Key health statistics
from general practice 1998. Analyses of morbidity and
treatment data, including time trends, England and
Wales. Series MB6 No. 2, 2000. URL:
http://www.statistics.gov.uk/downloads/
theme_health/Key_Health_Stats_1998.pdf

138. Brennan J, Johansen A, Butler J, Stone M,
Richmond P, Jones S, et al. Place of residence and
risk of fracture in older people: a population-
based study of over 65-year-olds in Cardiff.
Osteoporos Int 2003;14:515–19.

139. Monthly index of medical specialties. London:
Haymarket Medical Publications; 2006.

140. Brazier JE, Kang K, Carlton J, Czoski-Murray CJ.
General population survey to obtain values for AMD
visual impairment states using lenses – preliminary
report. 2006. Appendix 1. Lucentis (ranibizumab)
therapy for the treatment of wet age-related
macular degeneration. Evidence submitted to the
National Institute for Clinical Excellence. Novartis
Pharmaceuticals; August 2006.

141. Miller DK, Homan SM. Determining transition-
probabilities – confusion and suggestions. Med
Decis Making 1994;14:52–8.

142. Mills E, Heels-Ansdell D, Kelly S, Guyatt G. A
randomized trial of pegaptanib sodium for age-
related macular degeneration used an innovative
design to explore disease-modifying effects. J Clin
Epidemiol 2007;60:456–60.

143. Sharma S, Brown GC, Brown MM, Shah GK,
Snow K, Brown H, et al. Converting visual acuity to
utilities. Can J Ophthalmol 2000;35:267–72.

144. Knapp M, Beecham J, Fenyo A, Hallam A.
Community mental health care for former hospital
in-patients. Predicting costs from needs and
diagnoses. Br J Psychiatry 1995;166 (Suppl 27):
10–18.

145. Scottish Medicines Consortium. Pegaptanib 0.3 mg,
solution for intravitreal injection (Macugen). No.
290/06. Accessed 6 November 2006.
http://www.scottishmedicines.co.uk

146. Meads C, Hyde C. What is the cost of blindness?
Br J Ophthalmol 2003;87:1201–4.

147. McLaughlan B, Winyard S. Left to pay for their own.
How people facing sight loss from wet age-related
macular degeneration are let down by the NHS. Report
on the availability of anti-VEGF treatments for wet age-
related macular degeneration. Accessed 27 October
2006. http://www.rnib.org.uk/xpedio/groups/public/
documents/publicwebsite/public_macugenreport.doc

148. Evers S, Goossens M, de Vet H, van Tulder M,
Ament A. Criteria list for assessment of
methodological quality of economic evaluations:
Consensus on Health Economic Criteria. Int J
Technol Assess Health Care 2005;21:240–5.

149. Brody BL, Roch-Levecq AC, Gamst AC, Maclean K,
Kaplan RM, Brown SI. Self-management of age-

References

106

Page 237

How to obtain copies of this and other HTA Programme reports.
An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of
charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is
also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and
private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is
£2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

– fax (with credit card or official purchase order)
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your
order and then post or fax it.

Contact details are as follows:
HTA Despatch Email: [email protected]
c/o Direct Mail Works Ltd Tel: 02392 492 000
4 Oakwood Business Centre Fax: 02392 478 555
Downley, HAVANT PO9 2NP, UK Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of
£100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300
per volume. Please see our website for details. Subscriptions can only be purchased for the current or
forthcoming volume.

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd
and drawn on a bank with a UK address.

Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard,
Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.
We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see
contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various
committees.

HTA

Page 238

Ranibizumab and pegaptanib for the
treatment of age-related macular
degeneration: a systematic review
and economic evaluation

JL Colquitt, J Jones, SC Tan, A Takeda, AJ Clegg
and A Price

Health Technology Assessment 2008; Vol. 12: No. 16

HTAHealth Technology AssessmentNHS R&D HTA Programme
www.hta.ac.uk

The National Coordinating Centre for Health Technology Assessment,
Alpha House, Enterprise Road
Southampton Science Park
Chilworth
Southampton SO16 7NS, UK.
Fax: +44 (0) 23 8059 5639 Email: [email protected]
http://www.hta.ac.uk ISSN 1366-5278

Feedback
The HTA Programme and the authors would like to know

your views about this report.

The Correspondence Page on the HTA website
(http://www.hta.ac.uk) is a convenient way to publish

your comments. If you prefer, you can send your comments
to the address below, telling us whether you would like

us to transfer them to the website.

We look forward to hearing from you.

May 2008

H
ealth Technology Assessm

ent 2008;V
ol. 12: N

o. 16
R

anibizum
ab and pegaptanib for the treatm

ent of age-related m
acular degeneration

Similer Documents